This plain language summary from Future Rare Diseases describes the results of the MOVE study, which investigated the drug palovarotene in the treatment of patients with fibrodysplasia ossificans progressiva (FOP).
Read the full article here.
The original article on which this plain language summary is based is titled ‘Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)’ and was published in the Journal of Bone and Mineral Research. Read the original article here.